23.37 -0.21 (-0.89%)
MYGN
| Trade MYGN now with |
Stock Details
Last Trade:23.37 Change:-0.21 (-0.89%) Prev Close:23.58 Open: 23.49 Days Range:23.12 – 23.51 52 Week Range: 17.51 - 25.89 Volume:419198 P/E: 19.00EPS:1.23
View AllRecent Alerts 02/09/12
Recent Alert on 02/02/12 at 4:14pm
Myriad Genetics (MYGN) Announces Test Results Which Significantly Predict Biochemical Recurrence Risk After Prostatectomy
Myriad Genetics (MYGN) Announces Test Results Which Significantly Predict Biochemical Recurrence Risk After Prostatectomy
Myriad Genetics, Inc. (Nasdaq: MYGN) announced that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday,... Read More
Recent Alert on 02/01/12 at 11:16am
Auriga Reiterates a 'Buy' on Myriad Genetics (MYGN); F2Q12 Results: Nice Beat & Raise as Colaris Continues to Surprise
Auriga Reiterates a 'Buy' on Myriad Genetics (MYGN); F2Q12 Results: Nice Beat & Raise as Colaris Continues to Surprise
Recent Alert on 01/31/12 at 6:13pm
After-Hours Movers 01/31: (KTCC) (AZPN) (FTNT) Higher; (AMZN) (UBNT) (CCUR) (CHRW) Lower
After-Hours Movers 01/31: (KTCC) (AZPN) (FTNT) Higher; (AMZN) (UBNT) (CCUR) (CHRW) Lower
Recent Alert on 01/31/12 at 4:09pm
Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
Recent Alert on 01/31/12 at 4:09pm
Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
View AllRecent Press Releases
Press Release on 02/06/12 at 4:15pm
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference
Press Release on 02/06/12 at 3:47pm
Mintz Levin’s Life Sciences Practice Represents Clients in More Than $3 Billion in Life Sciences Deals in 2011
Mintz Levin’s Life Sciences Practice Represents Clients in More Than $3 Billion in Life Sciences Deals in 2011
View AllRecent SEC Filings
SEC Filing on 02/09/12 at 4:17pm
Form SC 13G/A MYRIAD GENETICS INC Filed by: Capital Research Global Investors
Form SC 13G/A MYRIAD GENETICS INC Filed by: Capital Research Global Investors
SEC Filing on 02/09/12 at 12:20pm
Form SC 13G/A MYRIAD GENETICS INC Filed by: RS INVESTMENT MANAGEMENT CO LLC
Form SC 13G/A MYRIAD GENETICS INC Filed by: RS INVESTMENT MANAGEMENT CO LLC
View AllRecent Blog Posts
Blog Posts on 01/11/12 at 10:13pm
Myriad Genetics' CEO Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)
Myriad Genetics' CEO Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)
Blog Posts on 12/14/11 at 1:30pm
Myriad Genetics' Management Presents at 22nd Annual Oppenheimer Healthcare Conference - Conference Call Transcript
Myriad Genetics' Management Presents at 22nd Annual Oppenheimer Healthcare Conference - Conference Call Transcript


